Research & Development: Page 43
-
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma Pool Marcello Agosti Takeda Names Head of New Global Commercial Organization Takeda has named Marcello Agosti head of global commercial, based in Zurich. The company established the global commercial organization as part of its plans to structure operations to become more agile and custome...
By PharmaVoice Team • Aug. 1, 2015 -
PharmaVoice Team/PharmaVoice
Who's On The List by Section
Commanders & Chiefs Dr. Michelle Berrey Chimerix Rob Cosinuke athenahealth and Epocrates Jim Curtis Remedy Health Media Dr. Bruce Feinberg Cardinal Health Specialty Solutions Lisa Giles Giles & Associates Consultancy Inc. and Optivara Inc. Peter Goldschmidt Sandoz Inc. D...
By PharmaVoice Team • Aug. 1, 2015 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Researchers & Scientists
Dr. Anish Suri Title: Senior Scientific Director, Discovery Immunology Company: Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson Education: Ph.D., Immunology, Washington University St. Louis; B.S., Biology, Angelo State University Famil...
By PharmaVoice Team • Aug. 1, 2015 -
PharmaVoice Team/PharmaVoice
Fun Facts About the PharmaVOICE 100
Where they were born? The PharmaVOICE 100 may come from all over, but what they have in common is a sincere desire to improve the lives of patients everywhere. What was their first job? We thought it would be fun to know how these highly successful executives earned their first paychecks. As it t...
By PharmaVoice Team • Aug. 1, 2015 -
PharmaVoice Team/PharmaVoice
Overcoming the Challenges that Hinder Innovation
PharmaVOICE 100 honorees discuss the challenges that the industry needs to overcome to support future innovation. Between 2009 and 2014, the annual growth rate for the top 25 life-sciences companies slowed from the prior decade’s double-digit average to only 1% annually, according to a recent rep...
By PharmaVoice Team • Aug. 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovation In a Patient-Centric World
From healthcare reform to the push for value in medicines to personalized healthcare, the patient is now at the center of, well, everything. This means that pharmaceutical companies are now required to create a new paradigm, with the patient at the center. An initiative that began last year withi...
By PharmaVoice Team • Aug. 1, 2015 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In the rare disease community there is saying: Alone we are rare, together we are strong. Wendy White, senior VP, for rare diseases, at Dohmen Life Science Services, a board member of Global Genes, and the president of the Heathcare Businesswomen’s Association (HBA), shared her personal rare dis...
By Taren Grom • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
The 3D Human Body Frank Sculli, Co-founder and CEO of BioDigital, talks about his company’s 3D technology that can produce a virtual model of the human body to help everyone better understand health and disease concepts. The amount and complexity of health information continues to grow, but the w...
By Frank Sculli • June 1, 2015 -
PharmaVoice Team/PharmaVoice
The Network
IBM Partners For Advanced Health Data Collection Trending Now: Apps and partnerships extend medical reach and research. IBM has established a Watson Health Cloud that will provide a secure and open platform for physicians, researchers, insurers, and companies focused on health and wellness soluti...
By PharmaVoice Team • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Wearables in Clinical Trials
Wearables are emerging as a solution for creating a more nimble and efficient clinical trial process, from recruiting patients to collecting real-world patient data. While the movement is still in its infancy and there are several challenges and hurdles to overcome before wearables become commonp...
By Robin Robinson • June 1, 2015 -
PharmaVoice Team/PharmaVoice
The Importance of CROs For Oncology Trials
Oncology trials are different from trials in other therapeutic areas. They are often more complex, involve adaptive design, and can include biomarker and companion diagnostics. They require CROs with therapeutic experience and the knowledge and skills to address these more complex studies. Cancer...
By Denise Myshko • June 1, 2015 -
PharmaVoice Team/PharmaVoice
2015 DIA Preview
The DIA Annual Meeting brings together key thought leaders and innovators from industry, academia, government and regulatory agencies, health, patient, and philanthropic organizations from around the globe and across all disciplines involved in the discovery, development, and life-cycle managemen...
By PharmaVoice Team • June 1, 2015 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Clinical Solutions: Clinical Services Market Poised For Growth
According to a recent report from JZ Med, the global clinical trial service market is expected to reach more than $64 billion by 2020, up from $38.4 billion at present, representing a CAGR of 9% between 2015 and 2020. By 2020 the average clinical trial outsourcing penetration will likely reach ar...
By PharmaVoice Team • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Endpoint-Based Protocol Development: An Outcomes-Based Approach to Clinical Trial Testing
A shift toward more targeted therapeutics, combined with the need to meet specific endpoints in clinical trials, has placed a significant emphasis on esoteric laboratory tests within the test menus employed in clinical trials. Biopharmaceutical companies and clinical research organizations have l...
By Mark Engelhart • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Patient or Partner? Building An Innovative Relationship for the Future
The healthcare industry has struggled with many changes in the last 10 years, including the inevitable patent cliff, the emergence of patient advocacy, increased regulatory and healthcare reform, and the rising cost of doing business. However, even in this age of rapid innovation and adaptability...
By Marc Sirockman • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Implementing Interactive Response Technology in A Software-As-A-Service Model
Historically, the software used in clinical trials has taken the form of either a fully installed customized solution, or a hybrid customized and configurable solution. The implementation of such systems has been time-consuming with costly infrastructure, and because minimizing IT delivery times ...
By Jamey McCarty • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Clinical Trial Transformation Through Digital Clinical and Code Halos
What is “Digital Clinical?" As Morpheus tells Neo in the film The Matrix, “No one can be told what the Matrix is. You have to see it for yourself." Today we sometimes find ourselves immersed in our own real-life version of the Matrix, as our personal data accumulates on computer servers somewhere...
By Larry Florin • June 1, 2015 -
PharmaVoice Team/PharmaVoice
The Importance of A Beautiful Technology Experience
Do you remember when the first Apple iPod was released? The advertisements on television showed beautiful images of rotating color behind a clean silhouette dancing to the sounds coming from the earbuds. It was bold, fresh, and exciting. It was fun. We were not confused by technical specs. We wer...
By Ibraheem (IBS) Mahmood • June 1, 2015 -
PharmaVoice Team/PharmaVoice
How Do iComply? A Look at Regulatory Topics Surrounding the use of Mhealth Technology in Clinical Trials
The U.S. National Institutes of Health (NIH) Consensus Group has defined mHealth as “the use of mobile and wireless devices to improve health outcomes, health care services and health research." The mHealth landscape is expanding with over 97,000 apps (mobile applications) as of 2013. Yet the vas...
By Philip Coran • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Extracting Maximum Value From Electronic Data Capture
Electronic data capture (EDC) has been employed for clinical trial data for many years and is encouraged by the FDA because it provides significant benefits to sponsors, investigators, and patients, including more accurate data that can be more easily shared and monitored, increased compliance wi...
By Zaher El-Assi • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Which Patients Are Really at Risk For Becoming Non-Adherent?
If you’re targeting only the most obvious patients with your medication adherence programs, you’re missing out on a big opportunity. Quite often, outreach programs focus on individuals hovering around the 80% threshold for proportion of days covered (PDC). It makes sense. Why not use your resourc...
By Craig Schilling • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Seeing the Big Picture With Visual Data Analytics
Pharmaceutical and biotechnology companies are facing a gigantic increase in data — not just in volume, but in complexity. The number of clinical trials in the National Institute of Health’s registry has jumped from 5,635 in 2000 to 183,991 in 2015 — an increase of more than 30 times. The data la...
By Greg Moody • June 1, 2015 -
PharmaVoice Team/PharmaVoice
All Monitoring is Risk Based
Drug developers must introduce innovation across the entire life cycle of product development to more effectively bring new therapies to markets. The innovations will be recognized by the use of smarter and faster methods for discovery of new drug entities and companion diagnostics, use of flexib...
By Michael Brooks • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Managing the Scientific and Ethical Complexities of Medical Innovation
Today, advances in science and medicine are occurring at an unprecedented pace. These exciting changes broaden the ethical implications of medical innovation and expand the need to protect clinical research subjects. Often, Institutional Review Boards (IRBs) find themselves on the frontline of th...
By Lindsay McNair • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Maximizing Portfolio Value By Smart Partnering: This is Not Your Father's Oldsmobile
Portfolio value is traditionally associated with innovation value; i.e., intellectual property, market attractiveness, potential clinical utility, and other product-centric attributes. Less commonly considered is the differentiation afforded by the partnering process employed during clinical deve...
By Michael Murphy • June 1, 2015
Previous
